Some novel therapies that target SLAMF7 in MM cells include elotuzumab (a humanized IgG1 kappa monoclonal antibody) and chimeric antigen receptor-T cells (CAR-T). This evidence concerns the gene SLAMF7 and Miyoshi myopathy.